PIONEER FUND
SWV ARE COMMISSIONING TRIALS OF MDMA-ASSISTED PSYCHOTHERAPY: A POTENTIAL BREAKTHROUGH IN PTSD TREATMENT
For too many UK veterans, the battle isn’t over when combat ends.
Nearly one in five UK combat veterans suffers from Post-Traumatic Stress Disorder or PTSD. And it’s been estimated that one third to one half of PTSD cases overall are resistant to treatment.
Their struggle with PTSD can be all-consuming and at times overwhelming.
But PTSD therapy is a challenge in itself – and for many veterans current therapies offer only a modest chance of success. Most therapies for PTSD require patients to relive the trauma over and over – and the painful emotions that involves limits the effectiveness of the treatment.
Now, researchers have developed a new form of PTSD treatment – MDMA-assisted psychotherapy. This potential breakthrough approach uses medical doses of MDMA to reduce the fear response and help patients access their innate capacity for resilience and for post-traumatic growth. MDMA enhances psychotherapy by enabling patients to better process the trauma with the aid of their psychotherapists.
Supporting Wounded Veterans is proud to join the worldwide research programme assessing what may well prove to be a remarkable treatment. At the one year follow-up to Phase 2 Trials, 67 percent of study participants no longer qualified for a diagnosis of PTSD.
To find out more about PTSD and this highly promising new therapy, and to learn about the upcoming trial, click on the links below.
SUPPORTING WOUNDED VETERANS’ MDMA-ASSISTED PSYCHOTHERAPY PROGRAMME
As part of their support for the programme Supporting Wounded Veterans are able to offer Veterans who volunteer the opportunity to explore the benefits of MDMA-assisted psychotherapy, and by doing so to contribute to research, by participating in a trial at King's College London
We are raising funds for 20 or more veterans to take part in the upcoming Phase 2 and 3 trials at King’s College London. The Phase 3 study planned to start in 2021 will be a substantial part of the application to the European Medicines Agency.The EMA has agreed that it will accept data submitted for FDA approval for MDMA – anticipated in 2022 or early 2023 if results are positive – and require an additional 70 people go through the European trials.
We support this research because we hope it will be a game-changer in this complex and difficult field, and because it is fully consistent with our purpose - that we, together, can make a change and help veterans overcome the challenges they face.
